Antimicrobial resistance has made it increasingly important to identify which antibiotics are likely to work against a bacterial infection. For resistant Gram-negative bacteria, susceptibility testing helps healthcare professionals evaluate laboratory evidence and make informed treatment decisions.
Aztreonam + avibactam is particularly relevant to discussions about certain beta-lactamase-producing bacteria. Understanding how susceptibility testing is performed, how results are interpreted, and what limitations exist can help explain the role of this combination in antimicrobial resistance management.
What Is Aztreonam + Avibactam Susceptibility Testing?
Susceptibility testing is a laboratory process used to assess how a bacterial isolate responds to an antimicrobial agent under defined testing conditions.
For aztreonam + avibactam, testing is important because the combination’s activity depends on the bacterial species, its resistance mechanisms, and the testing method used.
A result should be interpreted according to validated laboratory methods and applicable clinical breakpoints. The presence of a particular resistance gene alone does not necessarily establish the complete susceptibility profile of an isolate.
Why Is Susceptibility Testing Important?
Some Gram-negative bacteria produce enzymes that reduce the effectiveness of beta-lactam antibiotics. These enzymes include extended-spectrum beta-lactamases, AmpC beta-lactamases, and carbapenemases.
Metallo-beta-lactamases (MBLs), including NDM, VIM, and IMP, are particularly important because they can inactivate many beta-lactam antibiotics.
Aztreonam is not hydrolysed by MBLs. However, bacteria may produce additional beta-lactamases that can affect aztreonam. Avibactam inhibits several other beta-lactamase classes, which explains the scientific rationale for combining the two agents.
Susceptibility testing helps assess whether this mechanism translates into activity against an individual bacterial isolate. The result cannot be assumed from the resistance mechanism alone.
Common Approaches to Antimicrobial Susceptibility Testing
Different laboratory methods are available for evaluating antimicrobial susceptibility. The appropriate method depends on the organism, antimicrobial agent, validated testing procedure, and applicable standards.
1. Broth Microdilution
Broth microdilution evaluates bacterial growth in liquid media containing defined antimicrobial concentrations. It can be used to determine the minimum inhibitory concentration (MIC), which is the lowest tested concentration that prevents visible bacterial growth under the specified conditions.
For combination agents, the testing procedure must account for the relevant components and follow the validated method.
2. Agar-Based Methods
Some susceptibility tests use agar media to assess bacterial growth in the presence of an antimicrobial agent. These methods can be useful when an appropriate, validated procedure and interpretive criteria are available for the specific organism and drug combination.
Not every agar-based method is appropriate for every antimicrobial combination. Laboratories must follow the applicable testing guidance.
3. Minimum Inhibitory Concentration Interpretation
The MIC is a laboratory measurement, not a standalone treatment recommendation. Its interpretation depends on the organism, the antimicrobial agent, the testing method, and the relevant clinical breakpoint.
A lower MIC does not automatically establish clinical success, and an MIC should not be interpreted using breakpoints intended for a different agent or testing configuration.
Understanding the Role of MBLs in Test Interpretation
MBLs can complicate the treatment of infections caused by resistant Gram-negative bacteria. They hydrolyse many beta-lactam antibiotics but do not hydrolyse aztreonam.
However, MBL-producing organisms may also carry other beta-lactamase enzymes. These additional enzymes may compromise aztreonam activity, which is why the complementary role of avibactam is important.
Laboratory evaluation should therefore consider the overall resistance profile rather than relying only on whether an MBL gene is detected.
Additional resistance mechanisms, bacterial permeability changes, and other isolate-specific characteristics may also influence the final result.
What Do Susceptibility Results Mean?
Laboratory reports should be interpreted using the standards and breakpoints applicable to the particular organism and antimicrobial agent.
Depending on the validated interpretive system, results may be categorised as susceptible, intermediate or susceptible with increased exposure, or resistant. The exact categories and definitions differ across standards and should not be treated as interchangeable.
Healthcare professionals should consider susceptibility results alongside:
- The identified bacterial species.
- The site and severity of infection.
- The patient’s clinical condition.
- Relevant resistance mechanisms.
- Product-specific prescribing information.
- Current treatment guidelines and specialist advice.
A laboratory result supports clinical decision-making but does not replace it.
Limitations of Susceptibility Testing
Susceptibility testing has important limitations. Results may be affected by the testing method, the quality of the specimen, the organism being tested, and the interpretive criteria used.
For newer or specialised antimicrobial combinations, validated methods and appropriate breakpoints are especially important. A method designed for another antibiotic should not automatically be used to evaluate aztreonam + avibactam.
Laboratories should consult current guidance from recognised standards organisations and follow their validated procedures. If an appropriate interpretive criterion is unavailable, the result should not be assigned an unsupported susceptibility category.
Clinical Relevance of Aztreonam + Avibactam Injection
Susceptibility data can help healthcare professionals assess the potential relevance of aztreonam + avibactam in selected resistant Gram-negative infections.
The combination’s complementary mechanism is of particular scientific interest for certain MBL-producing organisms that may also express other beta-lactamases. Nevertheless, its activity must be assessed for the specific isolate, and clinical use depends on the relevant product’s approved information and applicable guidelines.
Dosing, administration, renal adjustment, contraindications, and safety precautions should be checked against the prescribing information for the exact product being considered. Information relating to one formulation or brand should not automatically be transferred to another.
Conclusion
Aztreonam + avibactam susceptibility testing is an important topic in the evaluation of selected resistant Gram-negative bacteria. Laboratory testing helps assess the activity of the combination, while appropriate interpretation ensures that results are not overstated or applied outside their validated context.
Understanding MIC measurements, resistance mechanisms, laboratory methods, and clinical breakpoints provides a more reliable basis for interpreting susceptibility data. As antimicrobial resistance evolves, validated testing and evidence-based clinical decisions remain essential.
Medical disclaimer: This article is intended for educational purposes only. It does not replace professional medical advice, laboratory guidance, or product-specific prescribing information.